Pharmafile

JANUARY 25, 2023

Lilly’s expansion is set to include the addition of further parenteral filling, device assembly and packaging capacity in order to meet the growing demand for the company’s incretin-based diabetes treatments and medications. read more

Packaging 52

Packaging Pharmaceutical Companies Pharmaceutical Companies Diabetes 52

European Pharmaceutical Review

FEBRUARY 22, 2023

1 Used to treat a range of chronic diseases (eg, diabetes, rheumatoid arthritis, psoriasis, Crohn’s disease, haemophilia, etc), it is projected that the sales of biologics will rise from $380 billion in 2022 to $416 billion in 2023, and to almost $600 billion in 2027. Diabetes Therapy. The Business Research Company.

Biosimilars 105

Biosimilars Diabetes Immunity Immunization 105

STAT

SEPTEMBER 12, 2024

This calls for celebration with a cup of stimulation, and we are opening a new package of pecan pie for the occasion. billion, between 2024 and 2027 in a concession to investors who have viewed the company’s outlays following its pandemic-era windfall as profligate, STAT writes. Sound familiar? Have a great day, everyone.

Packaging 139

Packaging Diabetes Vaccines 139

Pharmacy Times

JULY 7, 2025

Takeda will discontinue Gammagard S/D by December 2027, transitioning to the new low IgA formulation. Takeda has informed the FDA that the manufacturing of Gammagard S/D will cease in December 2027.

Pharmacy Technician 39

Pharmacy Technician Immunity Immunization Compounding Pharmacies 39